<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Current Alzheimer Research</journal-id><journal-title-group><journal-title xml:lang="en">Current Alzheimer Research</journal-title><trans-title-group xml:lang="ru"><trans-title>Current Alzheimer Research</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1567-2050</issn><issn publication-format="electronic">1875-5828</issn></journal-meta><article-meta><article-id pub-id-type="publisher-id">643702</article-id><article-id pub-id-type="doi">10.2174/0115672050301407240408033046</article-id><article-categories><subj-group subj-group-type="toc-heading"><subject>Medicine</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Post-Translational Modifications in Tau and Their Roles in Alzheimer's Pathology</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kalyaanamoorthy</surname><given-names>Subha</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Opare</surname><given-names>Stanley Kojo</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Xiaoxiao</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Ganesan</surname><given-names>Aravindhan</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Rao</surname><given-names>Praveen</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1"><institution>Department of Chemistry, University of Waterloo</institution></aff><aff id="aff2"><institution>Chemistry, University of Waterloo</institution></aff><pub-date date-type="pub" iso-8601-date="2024-01-01" publication-format="electronic"><day>01</day><month>01</month><year>2024</year></pub-date><volume>21</volume><issue>1</issue><fpage>24</fpage><lpage>49</lpage><history><date date-type="received" iso-8601-date="2025-01-07"><day>07</day><month>01</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Bentham Science Publishers</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Bentham Science Publishers</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://journals.eco-vector.com/1567-2050/article/view/643702">https://journals.eco-vector.com/1567-2050/article/view/643702</self-uri><abstract xml:lang="en"><p id="idm46041443392160">:Microtubule-Associated Protein Tau (also known as tau) has been shown to accumulate into paired helical filaments and neurofibrillary tangles, which are known hallmarks of Alzheimers disease (AD) pathology. Decades of research have shown that tau protein undergoes extensive post-translational modifications (PTMs), which can alter the protein's structure, function, and dynamics and impact the various properties such as solubility, aggregation, localization, and homeostasis. There is a vast amount of information describing the impact and role of different PTMs in AD pathology and neuroprotection. However, the complex interplay between these PTMs remains elusive. Therefore, in this review, we aim to comprehend the key post-translational modifications occurring in tau and summarize potential connections to clarify their impact on the physiology and pathophysiology of tau. Further, we describe how different computational modeling methods have helped in understanding the impact of PTMs on the structure and functions of the tau protein. Finally, we highlight the tau PTM-related therapeutics strategies that are explored for the development of AD therapy.</p></abstract><kwd-group xml:lang="en"><kwd>Alzheimer&amp;amp</kwd><kwd>rsquo</kwd><kwd>s disease</kwd><kwd>tau protein</kwd><kwd>post-translational modifications</kwd><kwd>phosphorylation</kwd><kwd>acetylation</kwd><kwd>methylation</kwd><kwd>nitration</kwd><kwd>glycosylation</kwd><kwd>glycation</kwd><kwd>truncation</kwd><kwd>deamidation</kwd><kwd>ubiquitination</kwd><kwd>sumoylation</kwd><kwd>computational modeling</kwd><kwd>therapeutic approaches.</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Jha, A.; Mukhopadhaya, K. Memory, cognitive impairment and dementia. In: Alzheimers Disease: Diagnosis and Treatment Guide; Springer International Publishing: Cham, 2021; pp. 1-20. doi: 10.1007/978-3-030-56739-2_1</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Matthews, K.A.; Xu, W.; Gaglioti, A.H.; Holt, J.B.; Croft, J.B.; Mack, D.; McGuire, L.C. Racial and ethnic estimates of Alzheimers disease and related dementias in the United States (20152060) in adults aged ≥65 years. Alzheimers Dement., 2019, 15(1), 17-24. doi: 10.1016/j.jalz.2018.06.3063 PMID: 30243772</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Alzheimers disease and related dementias. 2020. Available from: https://www.cdc.gov/aging</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Gauthier, S. World Alzheimer Report 2022: Life after diagnosis: Navigating treatment, care and support. In: World Alzheimer Reports; Benoist Chloe, W.W., Ed.; Alzheimers Disease International, 2022; p. 413.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Meyers, E.A.; Sexton, C.; Snyder, H.M.; Carrillo, M.C. Impact of Alzheimers association support and engagement in the AD/ADRD research community through the COVID-19 pandemic and beyond. Alzheimers Dement., 2023, 19(7), 3222-3225. doi: 10.1002/alz.13015 PMID: 36872646</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Tay, L.X.; Ong, S.C.; Tay, L.J.; Ng, T.; Parumasivam, T. Economic burden of alzheimers disease: A systematic review. Value Health Reg. Issues, 2024, 40, 1-12. doi: 10.1016/j.vhri.2023.09.008 PMID: 37972428</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Global action plan on the public health response to dementia 2017-2025. Ed.; World Health Organization. 2017</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Achúcarro, N. Elongated and stäbechenzellen cells: Neuroglic cells and granulo-adipose cells at the Ammon horn of the rabbit; Nicolás Moya, 1909.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Achúcarro, N. Notes on the structure and functions of neuroglia and in particular of neuroglia of the human cerebral cortex; Children of Nicolás Moya, 1914.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Kim, S.R.; Lee, J.M. Prothrombin kringle-2, a mediator of microglial activation: new insight in Alzheimers disease pathogenesis. Neural Regen. Res., 2022, 17(12), 2675-2676. doi: 10.4103/1673-5374.335813 PMID: 35662205</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Stelzmann, R.A.; Schnitzlein, H.N.; Murtagh, F.R.; Murtagh, F.R. An english translation of alzheimers 1907 paper, "über eine eigenartige erkankung der hirnrinde". Clin. Anat., 1995, 8(6), 429-431. doi: 10.1002/ca.980080612 PMID: 8713166</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Swerdlow, R.H.; Anderson, H.; Burns, J.M. Alzheimers disease. In: Encyclopedia of Clinical Neuropsychology; Kreutzer, J.S.; DeLuca, J.; Caplan, B., Eds.; Springer New York: New York, NY, 2011; pp. 105-110. doi: 10.1007/978-0-387-79948-3_290</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Mattson, M.P. Oxidative stress, perturbed calcium homeostasis, and immune dysfunction in Alzheimers disease. J. Neurovirol., 2002, 8(6), 539-550. doi: 10.1080/13550280290100978 PMID: 12476348</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Cabezas, I.L.; Batista, A.H.; Rol, G.P. The role of glial cells in Alzheimer disease: Potential therapeutic implications. Neurologia, 2014, 29(5), 305-309. doi: 10.1016/j.nrl.2012.10.006 PMID: 23246214</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Sahara, N.; Maeda, S.; Takashima, A. Tau oligomerization: A role for tau aggregation intermediates linked to neurodegeneration. Curr. Alzheimer Res., 2008, 5(6), 591-598. doi: 10.2174/156720508786898442 PMID: 19075586</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Hosokawa, M.; Masuda-Suzukake, M.; Shitara, H.; Shimozawa, A.; Suzuki, G.; Kondo, H.; Nonaka, T.; Campbell, W.; Arai, T.; Hasegawa, M. Development of a novel tau propagation mouse model endogenously expressing 3 and 4 repeat tau isoforms. Brain, 2022, 145(1), 349-361. doi: 10.1093/brain/awab289 PMID: 34515757</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Tsujikawa, K.; Hamanaka, K.; Riku, Y.; Hattori, Y.; Hara, N.; Iguchi, Y.; Ishigaki, S.; Hashizume, A.; Miyatake, S.; Mitsuhashi, S.; Miyazaki, Y.; Kataoka, M.; Jiayi, L.; Yasui, K.; Kuru, S.; Koike, H.; Kobayashi, K.; Sahara, N.; Ozaki, N.; Yoshida, M.; Kakita, A.; Saito, Y.; Iwasaki, Y.; Miyashita, A.; Iwatsubo, T.; Ikeuchi, T.; Miyata, T.; Sobue, G.; Matsumoto, N.; Sahashi, K.; Katsuno, M. Actin-binding protein filamin-A drives tau aggregation and contributes to progressive supranuclear palsy pathology. Sci. Adv., 2022, 8(21), eabm5029. doi: 10.1126/sciadv.abm5029 PMID: 35613261</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Lukiw, W.J. Recent advances in our molecular and mechanistic understanding of misfolded cellular proteins in alzheimers disease (AD) and prion disease (PrD). Biomolecules, 2022, 12(2), 166. doi: 10.3390/biom12020166 PMID: 35204666</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Petrozziello, T.; Bordt, E.A.; Mills, A.N.; Kim, S.E.; Sapp, E.; Devlin, B.A.; Obeng-Marnu, A.A.; Farhan, S.M.K.; Amaral, A.C.; Dujardin, S.; Dooley, P.M.; Henstridge, C.; Oakley, D.H.; Neueder, A.; Hyman, B.T.; Spires-Jones, T.L.; Bilbo, S.D.; Vakili, K.; Cudkowicz, M.E.; Berry, J.D.; DiFiglia, M.; Silva, M.C.; Haggarty, S.J.; Sadri-Vakili, G. Targeting tau mitigates mitochondrial fragmentation and oxidative stress in amyotrophic lateral sclerosis. Mol. Neurobiol., 2022, 59(1), 683-702. doi: 10.1007/s12035-021-02557-w PMID: 34757590</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Liang, S.Y.; Wang, Z.T.; Tan, L.; Yu, J.T. Tau toxicity in neurodegeneration. Mol. Neurobiol., 2022, 59(6), 3617-3634. doi: 10.1007/s12035-022-02809-3 PMID: 35359226</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Maeda, S.; Sahara, N.; Saito, Y.; Murayama, M.; Yoshiike, Y.; Kim, H.; Miyasaka, T.; Murayama, S.; Ikai, A.; Takashima, A. Granular tau oligomers as intermediates of tau filaments. Biochemistry, 2007, 46(12), 3856-3861. doi: 10.1021/bi061359o PMID: 17338548</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Gerson, J.E.; Sengupta, U.; Lasagna-Reeves, C.A.; Guerrero- Muñoz, M.J.; Troncoso, J.; Kayed, R. Characterization of tau oligomeric seeds in progressive supranuclear palsy. Acta Neuropathol. Commun., 2014, 2(1), 73. doi: 10.1186/2051-5960-2-73 PMID: 24927818</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Shafiei, S.S.; Guerrero-Muñoz, M.J.; Castillo-Carranza, D.L. Tau oligomers: Cytotoxicity, propagation, and mitochondrial damage. Front. Aging Neurosci., 2017, 9, 83. doi: 10.3389/fnagi.2017.00083 PMID: 28420982</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Peeraer, E.; Bottelbergs, A.; van Kolen, K.; Stancu, I.C.; Vasconcelos, B.; Mahieu, M.; Duytschaever, H.; Ver Donck, L.; Torremans, A.; Sluydts, E.; Van Acker, N.; Kemp, J.A.; Mercken, M.; Brunden, K.R.; Trojanowski, J.Q.; Dewachter, I.; Lee, V.M.Y.; Moechars, D. Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice. Neurobiol. Dis., 2015, 73, 83-95. doi: 10.1016/j.nbd.2014.08.032 PMID: 25220759</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Alquezar, C.; Arya, S.; Kao, A.W. Tau post-translational modifications: Dynamic transformers of tau function, degradation, and aggregation. Front. Neurol., 2021, 11, 595532. doi: 10.3389/fneur.2020.595532 PMID: 33488497</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Marcelli, S.; Corbo, M.; Iannuzzi, F.; Negri, L.; Blandini, F.; Nistico, R.; Feligioni, M. The involvement of post-translational modifications in alzheimers disease. Curr. Alzheimer Res., 2018, 15(4), 313-335. doi: 10.2174/1567205014666170505095109 PMID: 28474569</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Selkoe, D.J. The therapeutics of Alzheimers disease: Where we stand and where we are heading. Ann. Neurol., 2013, 74(3), 328-336. doi: 10.1002/ana.24001 PMID: 25813842</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Ashraf, G.; Greig, N.; Khan, T.; Hassan, I.; Tabrez, S.; Shakil, S.; Sheikh, I.; Zaidi, S.; Akram, M.; Jabir, N.; Firoz, C.; Naeem, A.; Alhazza, I.; Damanhouri, G.; Kamal, M. Protein misfolding and aggregation in Alzheimers disease and type 2 diabetes mellitus. CNS Neurol. Disord. Drug Targets, 2014, 13(7), 1280-1293. doi: 10.2174/1871527313666140917095514 PMID: 25230234</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Braak, H.; Braak, E. Staging of alzheimers disease-related neurofibrillary changes. Neurobiol. Aging, 1995, 16(3), 271-278. doi: 10.1016/0197-4580(95)00021-6 PMID: 7566337</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Iqbal, K.; Novak, M. From tangles to tau protein. Bratisl. Lek Listy, 2006, 107(9-10), 341-342. PMID: 17262984</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Fuentes, P.; Catalan, J. A clinical perspective: Anti taus treatment in Alzheimers disease. Curr. Alzheimer Res., 2011, 8(6), 686-688. doi: 10.2174/156720511796717221 PMID: 21605037</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Ceyzériat, K.; Zilli, T.; Millet, P.; Frisoni, G.B.; Garibotto, V.; Tournier, B.B. Learning from the past: A review of clinical trials targeting amyloid, tau and neuroinflammation in alzheimers disease. Curr. Alzheimer Res., 2020, 17(2), 112-125. doi: 10.2174/1567205017666200304085513 PMID: 32129164</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Cook, C.; Stankowski, J.N.; Carlomagno, Y.; Stetler, C.; Petrucelli, L. Acetylation: A new key to unlock taus role in neurodegeneration. Alzheimers Res. Ther., 2014, 6(3), 29. doi: 10.1186/alzrt259 PMID: 25031639</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Wegmann, S.; Biernat, J.; Mandelkow, E. A current view on Tau protein phosphorylation in Alzheimers disease. Curr. Opin. Neurobiol., 2021, 69, 131-138. doi: 10.1016/j.conb.2021.03.003 PMID: 33892381</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Park, S.; Lee, J.H.; Jeon, J.H.; Lee, M.J. Degradation or aggregation: The ramifications of post-translational modifications on tau. BMB Rep., 2018, 51(6), 265-273. doi: 10.5483/BMBRep.2018.51.6.077 PMID: 29661268</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Reily, C.; Stewart, T.J.; Renfrow, M.B.; Novak, J. Glycosylation in health and disease. Nat. Rev. Nephrol., 2019, 15(6), 346-366. doi: 10.1038/s41581-019-0129-4 PMID: 30858582</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Morishima-Kawashima, M.; Hasegawa, M.; Takio, K.; Suzuki, M.; Yoshida, H.; Watanabe, A.; Titani, K.; Ihara, Y. Hyperphosphorylation of Tau in PHF. Neurobiol. Aging, 1995, 16(3), 365-371. doi: 10.1016/0197-4580(95)00027-C PMID: 7566346</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Haukedal, H.; Freude, K.K. Implications of glycosylation in alzheimers disease. Front. Neurosci., 2021, 14, 625348. doi: 10.3389/fnins.2020.625348 PMID: 33519371</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Yang, X.J.; Seto, E. Lysine acetylation: Codified crosstalk with other posttranslational modifications. Mol. Cell, 2008, 31(4), 449-461. doi: 10.1016/j.molcel.2008.07.002 PMID: 18722172</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Funk, K.E.; Thomas, S.N.; Schafer, K.N.; Cooper, G.L.; Liao, Z.; Clark, D.J.; Yang, A.J.; Kuret, J. Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity. Biochem. J., 2014, 462(1), 77-88. doi: 10.1042/BJ20140372 PMID: 24869773</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Gong, C.X.; Liu, F.; Iqbal, K. O-GlcNAcylation: A regulator of tau pathology and neurodegeneration. Alzheimers Dement., 2016, 12(10), 1078-1089. doi: 10.1016/j.jalz.2016.02.011 PMID: 27126545</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Mondragón-Rodríguez, S. Phosphorylation of tau protein as the link between oxidative stress, mitochondrial dysfunction, and connectivity failure: Implications for Alzheimers disease. Oxid Med Cell Longev., 2013, 2013, 940603. doi: 10.1155/2013/940603</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Gong, C.X.; Liu, F.; Grundke-Iqbal, I.; Iqbal, K. Post-translational modifications of tau protein in Alzheimers disease. J. Neural Transm., 2005, 112(6), 813-838. doi: 10.1007/s00702-004-0221-0 PMID: 15517432</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Liu, F.; Zaidi, T.; Iqbal, K.; Grundke-Iqbal, I.; Merkle, R.K.; Gong, C.X. Role of glycosylation in hyperphosphorylation of tau in Alzheimers disease. FEBS Lett., 2002, 512(1-3), 101-106. doi: 10.1016/S0014-5793(02)02228-7 PMID: 11852060</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Ye, H.; Han, Y.; Li, P.; Su, Z.; Huang, Y. The role of post-translational modifications on the structure and function of tau protein. J. Mol. Neurosci., 2022, 72(8), 1557-1571. doi: 10.1007/s12031-022-02002-0 PMID: 35325356</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Mandel, N.; Agarwal, N. Role of SUMOylation in neurodegenerative diseases. Cells, 2022, 11(21), 3395. doi: 10.3390/cells11213395 PMID: 36359791</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Sarge, K.D.; Park-Sarge, O.K. SUMOylation and human disease pathogenesis. Trends Biochem. Sci., 2009, 34(4), 200-205. doi: 10.1016/j.tibs.2009.01.004 PMID: 19282183</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Stoothoff, W.H.; Johnson, G.V.W. Tau phosphorylation: Physiological and pathological consequences. Biochim. Biophys. Acta Mol. Basis Dis., 2005, 1739(2-3), 280-297. doi: 10.1016/j.bbadis.2004.06.017 PMID: 15615646</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Morris, M.; Knudsen, G.M.; Maeda, S.; Trinidad, J.C.; Ioanoviciu, A.; Burlingame, A.L.; Mucke, L. Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat. Neurosci., 2015, 18(8), 1183-1189. doi: 10.1038/nn.4067 PMID: 26192747</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Guillozet-Bongaarts, A.L.; Garcia-Sierra, F.; Reynolds, M.R.; Horowitz, P.M.; Fu, Y.; Wang, T.; Cahill, M.E.; Bigio, E.H.; Berry, R.W.; Binder, L.I. Tau truncation during neurofibrillary tangle evolution in Alzheimers disease. Neurobiol. Aging, 2005, 26(7), 1015-1022. doi: 10.1016/j.neurobiolaging.2004.09.019 PMID: 15748781</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Li, L.; Jiang, Y.; Wang, J.Z.; Liu, R.; Wang, X. Tau ubiquitination in alzheimers disease. Front. Neurol., 2022, 12, 786353. doi: 10.3389/fneur.2021.786353 PMID: 35211074</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Oliveira, J.; Costa, M.; de Almeida, M.S.C.; da Cruz e Silva, O.A.B.; Henriques, A.G. Protein phosphorylation is a key mechanism in Alzheimers disease. J. Alzheimers Dis., 2017, 58(4), 953-978. doi: 10.3233/JAD-170176 PMID: 28527217</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Tolnay, M.; Sergeant, N.; Ghestem, A.; Chalbot, S.; de Vos, R.A.; Jansen Steur, E.N.; Probst, A.; Delacourte, A. Argyrophilic grain disease and Alzheimers disease are distinguished by their different distribution of tau protein isoforms. Acta Neuropathol., 2002, 104(4), 425-434. doi: 10.1007/s00401-002-0591-z PMID: 12200631</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Drepper, F.; Biernat, J.; Kaniyappan, S.; Meyer, H.E.; Mandelkow, E.M.; Warscheid, B.; Mandelkow, E. A combinatorial native MS and LC-MS/MS approach reveals high intrinsic phosphorylation of human Tau but minimal levels of other key modifications. J. Biol. Chem., 2020, 295(52), 18213-18225. doi: 10.1074/jbc.RA120.015882 PMID: 33106314</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Kimura, T.; Sharma, G.; Ishiguro, K.; Hisanaga, S. Phospho-tau bar code: Analysis of phosphoisotypes of tau and its application to tauopathy. Front. Neurosci., 2018, 12, 44. doi: 10.3389/fnins.2018.00044 PMID: 29467609</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Hanger, D.P.; Anderton, B.H.; Noble, W. Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. Trends Mol. Med., 2009, 15(3), 112-119. doi: 10.1016/j.molmed.2009.01.003 PMID: 19246243</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Buée, L.; Bussière, T.; Buée-Scherrer, V.; Delacourte, A.; Hof, P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev., 2000, 33(1), 95-130. doi: 10.1016/S0165-0173(00)00019-9 PMID: 10967355</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Haj-Yahya, M. Site-specific hyperphosphorylation of tau inhibits its fibrillization in vitro, blocks its seeding capacity in cells, and disrupts its microtubule binding; Implications for the native state stabilization of tau. bioRxiv, 2019, 772046. doi: 10.1101/772046</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Zhou, X.W.; Li, X.; Bjorkdahl, C.; Sjogren, M.J.; Alafuzoff, I.; Soininen, H.; Grundke-Iqbal, I.; Iqbal, K.; Winblad, B.; Pei, J.J. Assessments of the accumulation severities of amyloid β-protein and hyperphosphorylated tau in the medial temporal cortex of control and Alzheimers brains. Neurobiol. Dis., 2006, 22(3), 657-668. doi: 10.1016/j.nbd.2006.01.006 PMID: 16513361</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>imić, G.; Babić Leko, M.; Wray, S.; Harrington, C.; Delalle, I.; Jovanov-Miloević, N.; Baadona, D.; Buée, L.; de Silva, R.; Di Giovanni, G.; Wischik, C.; Hof, P. Tau protein hyperphosphorylation and aggregation in Alzheimers disease and other tauopathies, and possible neuroprotective strategies. Biomolecules, 2016, 6(1), 6. doi: 10.3390/biom6010006 PMID: 26751493</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Su, J.H.; Cummings, B.J.; Cotman, C.W. Early phosphorylation of tau in Alzheimerʼs disease occurs at Ser-202 and is preferentially located within neurites. Neuroreport, 1994, 5(17), 2358-2362. doi: 10.1097/00001756-199411000-00037 PMID: 7533559</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Iqbal, K.; Grundke-Iqbal, I. Ubiquitination and abnormal phosphorylation of paired helical filaments in Alzheimers disease. Mol. Neurobiol., 1991, 5(2-4), 399-410. doi: 10.1007/BF02935561 PMID: 1726645</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Guillozet-Bongaarts, A.L.; Cahill, M.E.; Cryns, V.L.; Reynolds, M.R.; Berry, R.W.; Binder, L.I. Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: In vitro evidence and implications for tangle formation in vivo. J. Neurochem., 2006, 97(4), 1005-1014. doi: 10.1111/j.1471-4159.2006.03784.x PMID: 16606369</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Dickey, C.A.; Kamal, A.; Lundgren, K.; Klosak, N.; Bailey, R.M.; Dunmore, J.; Ash, P.; Shoraka, S.; Zlatkovic, J.; Eckman, C.B.; Patterson, C.; Dickson, D.W.; Nahman, N.S., Jr; Hutton, M.; Burrows, F.; Petrucelli, L. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J. Clin. Invest., 2007, 117(3), 648-658. doi: 10.1172/JCI29715 PMID: 17304350</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Hoover, B.R.; Reed, M.N.; Su, J.; Penrod, R.D.; Kotilinek, L.A.; Grant, M.K.; Pitstick, R.; Carlson, G.A.; Lanier, L.M.; Yuan, L.L.; Ashe, K.H.; Liao, D. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron, 2010, 68(6), 1067-1081. doi: 10.1016/j.neuron.2010.11.030 PMID: 21172610</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Lu, P.J.; Wulf, G.; Zhou, X.Z.; Davies, P.; Lu, K.P. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature, 1999, 399(6738), 784-788. doi: 10.1038/21650 PMID: 10391244</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Kondo, A.; Shahpasand, K.; Mannix, R.; Qiu, J.; Moncaster, J.; Chen, C.H.; Yao, Y.; Lin, Y.M.; Driver, J.A.; Sun, Y.; Wei, S.; Luo, M.L.; Albayram, O.; Huang, P.; Rotenberg, A.; Ryo, A.; Goldstein, L.E.; Pascual-Leone, A.; McKee, A.C.; Meehan, W.; Zhou, X.Z.; Lu, K.P. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature, 2015, 523(7561), 431-436. doi: 10.1038/nature14658 PMID: 26176913</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Lee, T.H.; Chen, C.H.; Suizu, F.; Huang, P.; Schiene-Fischer, C.; Daum, S.; Zhang, Y.J.; Goate, A.; Chen, R.H.; Zhou, X.Z.; Lu, K.P. Death-associated protein kinase 1 phosphorylates Pin1 and inhibits its prolyl isomerase activity and cellular function. Mol. Cell, 2011, 42(2), 147-159. doi: 10.1016/j.molcel.2011.03.005 PMID: 21497122</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Balastik, M.; Lim, J.; Pastorino, L.; Lu, K.P. Pin1 in Alzheimers disease: Multiple substrates, one regulatory mechanism? Biochim. Biophys. Acta Mol. Basis Dis., 2007, 1772(4), 422-429. doi: 10.1016/j.bbadis.2007.01.006 PMID: 17317113</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Buerger, K.; Ewers, M.; Pirttilä, T.; Zinkowski, R.; Alafuzoff, I.; Teipel, S.J.; DeBernardis, J.; Kerkman, D.; McCulloch, C.; Soininen, H.; Hampel, H. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimers disease. Brain, 2006, 129(11), 3035-3041. doi: 10.1093/brain/awl269 PMID: 17012293</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Gong, C.X.; Singh, T.J.; Grundke-Iqbal, I.; Iqbal, K. Phosphoprotein phosphatase activities in Alzheimer disease brain. J. Neurochem., 1993, 61(3), 921-927. doi: 10.1111/j.1471-4159.1993.tb03603.x PMID: 8395566</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>Chen, S.; Li, B.; Grundke-Iqbal, I.; Iqbal, K. I1PP2A affects tau phosphorylation via association with the catalytic subunit of protein phosphatase 2A. J. Biol. Chem., 2008, 283(16), 10513-10521. doi: 10.1074/jbc.M709852200 PMID: 18245083</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>Hart, G.W.; Slawson, C.; Ramirez-Correa, G.; Lagerlof, O. Cross talk between O-GlcNAcylation and phosphorylation: Roles in signaling, transcription, and chronic disease. Annu. Rev. Biochem., 2011, 80(1), 825-858. doi: 10.1146/annurev-biochem-060608-102511 PMID: 21391816</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Liu, F.; Iqbal, K.; Grundke-Iqbal, I.; Hart, G.W.; Gong, C.X. O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimers disease. Proc. Natl. Acad. Sci. USA, 2004, 101(29), 10804-10809. doi: 10.1073/pnas.0400348101 PMID: 15249677</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>ODonnell, N.; Zachara, N.E.; Hart, G.W.; Marth, J.D. Ogt-dependent X-chromosome-linked protein glycosylation is a requisite modification in somatic cell function and embryo viability. Mol. Cell. Biol., 2004, 24(4), 1680-1690. doi: 10.1128/MCB.24.4.1680-1690.2004 PMID: 14749383</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>Soeda, Y.; Takashima, A. New insights into drug discovery targeting tau protein. Front. Mol. Neurosci., 2020, 13, 590896. doi: 10.3389/fnmol.2020.590896 PMID: 33343298</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation>Carlomagno, Y.; Chung, D.C.; Yue, M.; Castanedes-Casey, M.; Madden, B.J.; Dunmore, J.; Tong, J.; DeTure, M.; Dickson, D.W.; Petrucelli, L.; Cook, C. An acetylationphosphorylation switch that regulates tau aggregation propensity and function. J. Biol. Chem., 2017, 292(37), 15277-15286. doi: 10.1074/jbc.M117.794602 PMID: 28760828</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation>Xia, Y.; Bell, B.M.; Giasson, B.I. Tau K321/K353 pseudoacetylation within KXGS motifs regulates taumicrotubule interactions and inhibits aggregation. Sci. Rep., 2021, 11(1), 17069. doi: 10.1038/s41598-021-96627-7 PMID: 34426645</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation>Julien, C.; Tremblay, C.; Émond, V.; Lebbadi, M.; Salem, N., Jr; Bennett, D.A.; Calon, F. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J. Neuropathol. Exp. Neurol., 2009, 68(1), 48-58. doi: 10.1097/NEN.0b013e3181922348 PMID: 19104446</mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation>Min, S.W.; Cho, S.H.; Zhou, Y.; Schroeder, S.; Haroutunian, V.; Seeley, W.W.; Huang, E.J.; Shen, Y.; Masliah, E.; Mukherjee, C.; Meyers, D.; Cole, P.A.; Ott, M.; Gan, L. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron, 2010, 67(6), 953-966. doi: 10.1016/j.neuron.2010.08.044 PMID: 20869593</mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation>Gorsky, M.K.; Burnouf, S.; Dols, J.; Mandelkow, E.; Partridge, L. Acetylation mimic of lysine 280 exacerbates human Tau neurotoxicity in vivo. Sci. Rep., 2016, 6(1), 22685. doi: 10.1038/srep22685 PMID: 26940749</mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation>Cohen, T.J.; Guo, J.L.; Hurtado, D.E.; Kwong, L.K.; Mills, I.P.; Trojanowski, J.Q.; Lee, V.M.Y. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun., 2011, 2(1), 252. doi: 10.1038/ncomms1255 PMID: 21427723</mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation>Min, S.W.; Chen, X.; Tracy, T.E.; Li, Y.; Zhou, Y.; Wang, C.; Shirakawa, K.; Minami, S.S.; Defensor, E.; Mok, S.A.; Sohn, P.D.; Schilling, B.; Cong, X.; Ellerby, L.; Gibson, B.W.; Johnson, J.; Krogan, N.; Shamloo, M.; Gestwicki, J.; Masliah, E.; Verdin, E.; Gan, L. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat. Med., 2015, 21(10), 1154-1162. doi: 10.1038/nm.3951 PMID: 26390242</mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation>Boulton, T.G.; Yancopoulos, G.D.; Gregory, J.S.; Slaughter, C.; Moomaw, C.; Hsu, J.; Cobb, M.H. An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control. Science, 1990, 249(4964), 64-67. doi: 10.1126/science.2164259 PMID: 2164259</mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation>Cohen, T.J.; Friedmann, D.; Hwang, A.W.; Marmorstein, R.; Lee, V.M.Y. The microtubule-associated tau protein has intrinsic acetyltransferase activity. Nat. Struct. Mol. Biol., 2013, 20(6), 756-762. doi: 10.1038/nsmb.2555 PMID: 23624859</mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation>Cohen, T.J.; Constance, B.H.; Hwang, A.W.; James, M.; Yuan, C.X. Intrinsic tau acetylation is coupled to auto-proteolytic tau fragmentation. PLoS One, 2016, 11(7), e0158470. doi: 10.1371/journal.pone.0158470 PMID: 27383765</mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation>Luo, Y.; Ma, B.; Nussinov, R.; Wei, G. Structural insight into tau proteins paradox of intrinsically disordered behavior, self-acetylation activity, and aggregation. J. Phys. Chem. Lett., 2014, 5(17), 3026-3031. doi: 10.1021/jz501457f PMID: 25206938</mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation>Sohn, P.D.; Tracy, T.E.; Son, H.I.; Zhou, Y.; Leite, R.E.P.; Miller, B.L.; Seeley, W.W.; Grinberg, L.T.; Gan, L. Acetylated tau destabilizes the cytoskeleton in the axon initial segment and is mislocalized to the somatodendritic compartment. Mol. Neurodegener., 2016, 11(1), 47. doi: 10.1186/s13024-016-0109-0 PMID: 27356871</mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation>Cook, C.; Carlomagno, Y.; Gendron, T.F.; Dunmore, J.; Scheffel, K.; Stetler, C.; Davis, M.; Dickson, D.; Jarpe, M.; DeTure, M.; Petrucelli, L. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum. Mol. Genet., 2014, 23(1), 104-116. doi: 10.1093/hmg/ddt402 PMID: 23962722</mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation>Yao, Z.; Gao, M.; Huang, Y. Acetylation of lysine residues within the MT-binding repeats specifically modulates the structure ensemble of Tau. FASEB J., 2018, 32(S1), lb34-lb34. doi: 10.1096/fasebj.2018.32.1_supplement.lb34</mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation>Thomas, S.N.; Funk, K.E.; Wan, Y.; Liao, Z.; Davies, P.; Kuret, J.; Yang, A.J. Dual modification of Alzheimers disease PHF-tau protein by lysine methylation and ubiquitylation: A mass spectrometry approach. Acta Neuropathol., 2012, 123(1), 105-117. doi: 10.1007/s00401-011-0893-0 PMID: 22033876</mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation>Balmik, A.A.; Chinnathambi, S. Methylation as a key regulator of Tau aggregation and neuronal health in Alzheimers disease. Cell Commun. Signal., 2021, 19(1), 51. doi: 10.1186/s12964-021-00732-z PMID: 33962636</mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation>Kontaxi, C.; Piccardo, P.; Gill, A.C. Lysine-directed post-translational modifications of tau protein in Alzheimers disease and related tauopathies. Front. Mol. Biosci., 2017, 4, 56. doi: 10.3389/fmolb.2017.00056 PMID: 28848737</mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation>Shams, H.; Matsunaga, A.; Ma, Q.; Mofrad, M.R.K.; Didonna, A. Methylation at a conserved lysine residue modulates tau assembly and cellular functions. Mol. Cell. Neurosci., 2022, 120, 103707. doi: 10.1016/j.mcn.2022.103707 PMID: 35231567</mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation>Bichmann, M.; Prat Oriol, N.; Ercan-Herbst, E.; Schöndorf, D.C.; Gomez Ramos, B.; Schwärzler, V.; Neu, M.; Schlüter, A.; Wang, X.; Jin, L.; Hu, C.; Tian, Y.; Ried, J.S.; Haberkant, P.; Gasparini, L.; Ehrnhoefer, D.E. SETD7-mediated monomethylation is enriched on soluble Tau in Alzheimers disease. Mol. Neurodegener., 2021, 16(1), 46. doi: 10.1186/s13024-021-00468-x PMID: 34215303</mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation>Wang, P.; Joberty, G.; Buist, A.; Vanoosthuyse, A.; Stancu, I.C.; Vasconcelos, B.; Pierrot, N.; Faelth-Savitski, M.; Kienlen-Campard, P.; Octave, J.N.; Bantscheff, M.; Drewes, G.; Moechars, D.; Dewachter, I. Tau interactome mapping based identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo. Acta Neuropathol., 2017, 133(5), 731-749. doi: 10.1007/s00401-016-1663-9 PMID: 28083634</mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation>Xu, Z.; Kohli, E.; Devlin, K.I.; Bold, M.; Nix, J.C.; Misra, S. Interactions between the quality control ubiquitin ligase CHIP and ubiquitin conjugating enzymes. BMC Struct. Biol., 2008, 8(1), 26. doi: 10.1186/1472-6807-8-26 PMID: 18485199</mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation>Petrucelli, L.; Dickson, D.; Kehoe, K.; Taylor, J.; Snyder, H.; Grover, A.; De Lucia, M.; McGowan, E.; Lewis, J.; Prihar, G.; Kim, J.; Dillmann, W.H.; Browne, S.E.; Hall, A.; Voellmy, R.; Tsuboi, Y.; Dawson, T.M.; Wolozin, B.; Hardy, J.; Hutton, M. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet., 2004, 13(7), 703-714. doi: 10.1093/hmg/ddh083 PMID: 14962978</mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation>Flach, K.; Ramminger, E.; Hilbrich, I.; Arsalan-Werner, A.; Albrecht, F.; Herrmann, L.; Goedert, M.; Arendt, T.; Holzer, M. Axotrophin/MARCH7 acts as an E3 ubiquitin ligase and ubiquitinates tau protein in vitro impairing microtubule binding. Biochim. Biophys. Acta Mol. Basis Dis., 2014, 1842(9), 1527-1538. doi: 10.1016/j.bbadis.2014.05.029 PMID: 24905733</mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation>Babu, J.R.; Geetha, T.; Wooten, M.W. Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J. Neurochem., 2005, 94(1), 192-203. doi: 10.1111/j.1471-4159.2005.03181.x PMID: 15953362</mixed-citation></ref><ref id="B101"><label>101.</label><mixed-citation>Cripps, D.; Thomas, S.N.; Jeng, Y.; Yang, F.; Davies, P.; Yang, A.J. Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J. Biol. Chem., 2006, 281(16), 10825-10838. doi: 10.1074/jbc.M512786200 PMID: 16443603</mixed-citation></ref><ref id="B102"><label>102.</label><mixed-citation>Morishima-Kawashima, M.; Hasegawa, M.; Takio, K.; Suzuki, M.; Titani, K.; Ihara, Y. Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron, 1993, 10(6), 1151-1160. doi: 10.1016/0896-6273(93)90063-W PMID: 8391280</mixed-citation></ref><ref id="B103"><label>103.</label><mixed-citation>Dolan, P.J.; Johnson, G.V.W. A caspase cleaved form of tau is preferentially degraded through the autophagy pathway. J. Biol. Chem., 2010, 285(29), 21978-21987. doi: 10.1074/jbc.M110.110940 PMID: 20466727</mixed-citation></ref><ref id="B104"><label>104.</label><mixed-citation>Puangmalai, N.; Sengupta, U.; Bhatt, N.; Gaikwad, S.; Montalbano, M.; Bhuyan, A.; Garcia, S.; McAllen, S.; Sonawane, M.; Jerez, C.; Zhao, Y.; Kayed, R. Lysine 63-linked ubiquitination of tau oligomers contributes to the pathogenesis of Alzheimers disease. J. Biol. Chem., 2022, 298(4), 101766. doi: 10.1016/j.jbc.2022.101766 PMID: 35202653</mixed-citation></ref><ref id="B105"><label>105.</label><mixed-citation>Perry, G.; Friedman, R.; Shaw, G.; Chau, V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc. Natl. Acad. Sci. USA, 1987, 84(9), 3033-3036. doi: 10.1073/pnas.84.9.3033 PMID: 3033674</mixed-citation></ref><ref id="B106"><label>106.</label><mixed-citation>García-Sierra, F.; Jarero-Basulto, J.J.; Kristofikova, Z.; Majer, E.; Binder, L.I.; Ripova, D. Ubiquitin is associated with early truncation of tau protein at aspartic acid(421) during the maturation of neurofibrillary tangles in Alzheimers disease. Brain Pathol., 2012, 22(2), 240-250. doi: 10.1111/j.1750-3639.2011.00525.x PMID: 21919991</mixed-citation></ref><ref id="B107"><label>107.</label><mixed-citation>Chakrabarty, R.; Yousuf, S.; Singh, M.P. Contributive role of hyperglycemia and hypoglycemia towards the development of alzheimers disease. Mol. Neurobiol., 2022, 59(7), 4274-4291. doi: 10.1007/s12035-022-02846-y PMID: 35503159</mixed-citation></ref><ref id="B108"><label>108.</label><mixed-citation>Weeraratna, A.T.; Kalehua, A.; DeLeon, I.; Bertak, D.; Maher, G.; Wade, M.S.; Lustig, A.; Becker, K.G.; Wood, W., III; Walker, D.G.; Beach, T.G.; Taub, D.D. Alterations in immunological and neurological gene expression patterns in Alzheimers disease tissues. Exp. Cell Res., 2007, 313(3), 450-461. doi: 10.1016/j.yexcr.2006.10.028 PMID: 17188679</mixed-citation></ref><ref id="B109"><label>109.</label><mixed-citation>Chenfei, Z.; Haizhen, Y.; Jie, X.; Na, Z.; Bo, X. Effects of aerobic exercise on hippocampal SUMOylation in APP/PS1 transgenic mice. Neurosci. Lett., 2022, 767, 136303. doi: 10.1016/j.neulet.2021.136303 PMID: 34695453</mixed-citation></ref><ref id="B110"><label>110.</label><mixed-citation>Dorval, V.; Fraser, P.E. Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and α-synuclein. J. Biol. Chem., 2006, 281(15), 9919-9924. doi: 10.1074/jbc.M510127200 PMID: 16464864</mixed-citation></ref><ref id="B111"><label>111.</label><mixed-citation>Luo, H.B.; Xia, Y.Y.; Shu, X.J.; Liu, Z.C.; Feng, Y.; Liu, X.H.; Yu, G.; Yin, G.; Xiong, Y.S.; Zeng, K.; Jiang, J.; Ye, K.; Wang, X.C.; Wang, J.Z. SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination. Proc. Natl. Acad. Sci. USA, 2014, 111(46), 16586-16591. doi: 10.1073/pnas.1417548111 PMID: 25378699</mixed-citation></ref><ref id="B112"><label>112.</label><mixed-citation>Nagaraju, P.G.; Priyadarshini, P. Tau-aggregation inhibition: Promising role of nanoencapsulated dietary molecules in the management of Alzheimers disease. Crit. Rev. Food Sci. Nutr., 2023, 63(32), 11153-11168. PMID: 35748395</mixed-citation></ref><ref id="B113"><label>113.</label><mixed-citation>Qin, M.; Li, H.; Bao, J.; Xia, Y.; Ke, D.; Wang, Q.; Liu, R.; Wang, J.Z.; Zhang, B.; Shu, X.; Wang, X. SET SUMOylation promotes its cytoplasmic retention and induces tau pathology and cognitive impairments. Acta Neuropathol. Commun., 2019, 7(1), 21. doi: 10.1186/s40478-019-0663-0 PMID: 30767764</mixed-citation></ref><ref id="B114"><label>114.</label><mixed-citation>Orsini, F. SUMO2 protects against tau-induced synaptic and cognitive dysfunction. bioRxiv, 2022. doi: 10.1101/2022.11.11.516192</mixed-citation></ref><ref id="B115"><label>115.</label><mixed-citation>Kovacech, B.; Novak, M. Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimers disease. Curr. Alzheimer Res., 2010, 7(8), 708-716. doi: 10.2174/156720510793611556 PMID: 20678071</mixed-citation></ref><ref id="B116"><label>116.</label><mixed-citation>Abraha, A.; Ghoshal, N.; Gamblin, T.C.; Cryns, V.; Berry, R.W.; Kuret, J.; Binder, L.I. C-terminal inhibition of tau assembly in vitro and in Alzheimers disease. J. Cell Sci., 2000, 113(21), 3737-3745. doi: 10.1242/jcs.113.21.3737 PMID: 11034902</mixed-citation></ref><ref id="B117"><label>117.</label><mixed-citation>Novak, M.; Kabat, J.; Wischik, C.M. Molecular characterization of the minimal protease resistant tau unit of the Alzheimers disease paired helical filament. EMBO J., 1993, 12(1), 365-370. doi: 10.1002/j.1460-2075.1993.tb05665.x PMID: 7679073</mixed-citation></ref><ref id="B118"><label>118.</label><mixed-citation>Loon, A.; Zamudio, F.; Sanneh, A.; Brown, B.; Smeltzer, S.; Brownlow, M.L.; Quadri, Z.; Peters, M.; Weeber, E.; Nash, K.; Lee, D.C.; Gordon, M.N.; Morgan, D.; Selenica, M.L.B. Accumulation of C-terminal cleaved tau is distinctly associated with cognitive deficits, synaptic plasticity impairment, and neurodegeneration in aged mice. Geroscience, 2022, 44(1), 173-194. doi: 10.1007/s11357-021-00408-z PMID: 34410588</mixed-citation></ref><ref id="B119"><label>119.</label><mixed-citation>Wischik, C.M.; Novak, M.; Thøgersen, H.C.; Edwards, P.C.; Runswick, M.J.; Jakes, R.; Walker, J.E.; Milstein, C.; Roth, M.; Klug, A. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1988, 85(12), 4506-4510. doi: 10.1073/pnas.85.12.4506 PMID: 3132715</mixed-citation></ref><ref id="B120"><label>120.</label><mixed-citation>Horta-Lopez, P.H. Association of α-1-antichymotrypsin expression with the development of conformational changes of tau protein in alzheimer's disease brain. Neuroscience, 2023, 518, 83-100. doi: 10.1016/j.neuroscience.2022.01.002</mixed-citation></ref><ref id="B121"><label>121.</label><mixed-citation>Flores-Rodríguez, P.; Ontiveros-Torres, M.A.; Cárdenas-Aguayo, M.C.; Luna-Arias, J.P.; Meraz-Ríos, M.A.; Viramontes-Pintos, A.; Harrington, C.R.; Wischik, C.M.; Mena, R.; Florán-Garduño, B.; Luna-Muñoz, J. The relationship between truncation and phosphorylation at the C-terminus of tau protein in the paired helical filaments of Alzheimers disease. Front. Neurosci., 2015, 9, 33. doi: 10.3389/fnins.2015.00033 PMID: 25717290</mixed-citation></ref><ref id="B122"><label>122.</label><mixed-citation>Gu, J.; Xu, W.; Jin, N.; Li, L.; Zhou, Y.; Chu, D.; Gong, C.X.; Iqbal, K.; Liu, F. Truncation of Tau selectively facilitates its pathological activities. J. Biol. Chem., 2020, 295(40), 13812-13828. doi: 10.1074/jbc.RA120.012587 PMID: 32737201</mixed-citation></ref><ref id="B123"><label>123.</label><mixed-citation>Ngian, Z.K.; Tan, Y.Y.; Choo, C.T.; Lin, W.Q.; Leow, C.Y.; Mah, S.J.; Lai, M.K.P.; Chen, C.L.H.; Ong, C.T. Truncated Tau caused by intron retention is enriched in Alzheimers disease cortex and exhibits altered biochemical properties. Proc. Natl. Acad. Sci. USA, 2022, 119(37), e2204179119. doi: 10.1073/pnas.2204179119 PMID: 36067305</mixed-citation></ref><ref id="B124"><label>124.</label><mixed-citation>Lo, C.H. Heterogeneous tau oligomers as molecular targets for alzheimers disease and related tauopathies. Biophysica, 2022, 2(4), 440-451. doi: 10.3390/biophysica2040039</mixed-citation></ref><ref id="B125"><label>125.</label><mixed-citation>Novak, P.; Cehlar, O.; Skrabana, R.; Novak, M. Tau conformation as a target for disease-modifying therapy: The role of truncation. J. Alzheimers Dis., 2018, 64(s1), S535-S546. doi: 10.3233/JAD-179942 PMID: 29865059</mixed-citation></ref><ref id="B126"><label>126.</label><mixed-citation>Smet-Nocca, C.; Broncel, M.; Wieruszeski, J.M.; Tokarski, C.; Hanoulle, X.; Leroy, A.; Landrieu, I.; Rolando, C.; Lippens, G.; Hackenberger, C.P.R. Identification of O-GlcNAc sites within peptides of the Tau protein and their impact on phosphorylation. Mol. Biosyst., 2011, 7(5), 1420-1429. doi: 10.1039/c0mb00337a PMID: 21327254</mixed-citation></ref><ref id="B127"><label>127.</label><mixed-citation>Sato, Y.; Naito, Y.; Grundke-Iqbal, I.; Iqbal, K.; Endo, T. Analysis of N -glycans of pathological tau: Possible occurrence of aberrant processing of tau in Alzheimers disease. FEBS Lett., 2001, 496(2-3), 152-160. doi: 10.1016/S0014-5793(01)02421-8 PMID: 11356201</mixed-citation></ref><ref id="B128"><label>128.</label><mixed-citation>Ledesma, M.D.; Bonay, P.; Colaço, C.; Avila, J. Analysis of microtubule-associated protein tau glycation in paired helical filaments. J. Biol. Chem., 1994, 269(34), 21614-21619. doi: 10.1016/S0021-9258(17)31849-5 PMID: 8063802</mixed-citation></ref><ref id="B129"><label>129.</label><mixed-citation>Liu, K.; Liu, Y.; Li, L.; Qin, P.; Iqbal, J.; Deng, Y.; Qing, H. Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property. Biochim. Biophys. Acta Mol. Basis Dis., 2016, 1862(2), 192-201. doi: 10.1016/j.bbadis.2015.12.002 PMID: 26655600</mixed-citation></ref><ref id="B130"><label>130.</label><mixed-citation>Ko, L.; Ko, E.C.; Nacharaju, P.; Liu, W.K.; Chang, E.; Kenessey, A.; Yen, S.H.C. An immunochemical study on tau glycation in paired helical filaments. Brain Res., 1999, 830(2), 301-313. doi: 10.1016/S0006-8993(99)01415-8 PMID: 10366687</mixed-citation></ref><ref id="B131"><label>131.</label><mixed-citation>Rungratanawanich, W.; Qu, Y.; Wang, X.; Essa, M.M.; Song, B.J. Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury. Exp. Mol. Med., 2021, 53(2), 168-188. doi: 10.1038/s12276-021-00561-7 PMID: 33568752</mixed-citation></ref><ref id="B132"><label>132.</label><mixed-citation>Lüth, H.J.; Ogunlade, V.; Kuhla, B.; Kientsch-Engel, R.; Stahl, P.; Webster, J.; Arendt, T.; Münch, G. Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimers disease brains. Cereb. Cortex, 2004, 15(2), 211-220. doi: 10.1093/cercor/bhh123 PMID: 15238435</mixed-citation></ref><ref id="B133"><label>133.</label><mixed-citation>Necula, M.; Kuret, J. Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro. J. Biol. Chem., 2004, 279(48), 49694-49703. doi: 10.1074/jbc.M405527200 PMID: 15364924</mixed-citation></ref><ref id="B134"><label>134.</label><mixed-citation>Yekta, R.; Sadeghi, L.; Dehghan, G. The role of non-enzymatic glycation on Tau-DNA interactions: Kinetic and mechanistic approaches. Int. J. Biol. Macromol., 2022, 207, 161-168. doi: 10.1016/j.ijbiomac.2022.02.178 PMID: 35257729</mixed-citation></ref><ref id="B135"><label>135.</label><mixed-citation>Limorenko, G.; Lashuel, H.A. Revisiting the grammar of Tau aggregation and pathology formation: How new insights from brain pathology are shaping how we study and target Tauopathies. Chem. Soc. Rev., 2022, 51(2), 513-565. doi: 10.1039/D1CS00127B PMID: 34889934</mixed-citation></ref><ref id="B136"><label>136.</label><mixed-citation>Reynolds, M.R.; Berry, R.W.; Binder, L.I. Site-specific nitration and oxidative dityrosine bridging of the τ protein by peroxynitrite: Implications for Alzheimers disease. Biochemistry, 2005, 44(5), 1690-1700. doi: 10.1021/bi047982v PMID: 15683253</mixed-citation></ref><ref id="B137"><label>137.</label><mixed-citation>Maina, M.B. Dityrosine cross-links are present in Alzheimers disease-derived tau oligomers and paired helical filaments (PHF) which promotes the stability of the PHF-core tau (297-391) in vitro. bioRxiv, 2022. doi: 10.1101/2022.05.28.493839</mixed-citation></ref><ref id="B138"><label>138.</label><mixed-citation>Butterfield, D.A.; Reed, T.T.; Perluigi, M.; De Marco, C.; Coccia, R.; Keller, J.N.; Markesbery, W.R.; Sultana, R. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: Implications for the role of nitration in the progression of Alzheimers disease. Brain Res., 2007, 1148, 243-248. doi: 10.1016/j.brainres.2007.02.084 PMID: 17395167</mixed-citation></ref><ref id="B139"><label>139.</label><mixed-citation>Reynolds, M.R.; Berry, R.W.; Binder, L.I. Site-specific nitration differentially influences τ assembly in vitro. Biochemistry, 2005, 44(42), 13997-14009. doi: 10.1021/bi051028w PMID: 16229489</mixed-citation></ref><ref id="B140"><label>140.</label><mixed-citation>Zhang, Y.J.; Xu, Y.F.; Liu, Y.H.; Yin, J.; Li, H.L.; Wang, Q.; Wang, J.Z. Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms. FASEB J., 2006, 20(9), 1431-1442. doi: 10.1096/fj.05-5223com PMID: 16816118</mixed-citation></ref><ref id="B141"><label>141.</label><mixed-citation>Weismiller, H.A.; Holub, T.J.; Krzesinski, B.J.; Margittai, M. A thiol-based intramolecular redox switch in four-repeat tau controls fibril assembly and disassembly. J. Biol. Chem., 2021, 297(3), 101021. doi: 10.1016/j.jbc.2021.101021 PMID: 34339733</mixed-citation></ref><ref id="B142"><label>142.</label><mixed-citation>Prifti, E. Mical modulates Tau toxicity via cysteine oxidation in vivo. Acta Neuropathol. Commun., 2022, 10(1), 1-19. PMID: 34980260</mixed-citation></ref><ref id="B143"><label>143.</label><mixed-citation>Schiffter, H.A. 5.41 - Pharmaceutical Proteins  Structure, Stability, and Formulation, in Comprehensive Biotechnology, 2nd ed; Academic Press: Burlington, 2011, pp. 521-541.</mixed-citation></ref><ref id="B144"><label>144.</label><mixed-citation>Watanabe, A.; Takio, K.; Ihara, Y. Deamidation and isoaspartate formation in smeared tau in paired helical filaments. Unusual properties of the microtubule-binding domain of tau. J. Biol. Chem., 1999, 274(11), 7368-7378. doi: 10.1074/jbc.274.11.7368 PMID: 10066801</mixed-citation></ref><ref id="B145"><label>145.</label><mixed-citation>Ebashi, M.; Toru, S.; Nakamura, A.; Kamei, S.; Yokota, T.; Hirokawa, K.; Uchihara, T. Detection of AD-specific four repeat tau with deamidated asparagine residue 279-specific fraction purified from 4R tau polyclonal antibody. Acta Neuropathol., 2019, 138(1), 163-166. doi: 10.1007/s00401-019-02012-0 PMID: 31006065</mixed-citation></ref><ref id="B146"><label>146.</label><mixed-citation>Dan, A.; Takahashi, M.; Masuda-Suzukake, M.; Kametani, F.; Nonaka, T.; Kondo, H.; Akiyama, H.; Arai, T.; Mann, D.M.A.; Saito, Y.; Hatsuta, H.; Murayama, S.; Hasegawa, M. Extensive deamidation at asparagine residue 279 accounts for weak immunoreactivity of tau with RD4 antibody in Alzheimers disease brain. Acta Neuropathol. Commun., 2013, 1(1), 54. doi: 10.1186/2051-5960-1-54 PMID: 24252707</mixed-citation></ref><ref id="B147"><label>147.</label><mixed-citation>Reynolds, M.R.; Reyes, J.F.; Fu, Y.; Bigio, E.H.; Guillozet-Bongaarts, A.L.; Berry, R.W.; Binder, L.I. Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimers disease and other tauopathies. J. Neurosci., 2006, 26(42), 10636-10645. doi: 10.1523/JNEUROSCI.2143-06.2006 PMID: 17050703</mixed-citation></ref><ref id="B148"><label>148.</label><mixed-citation>Lyons, A.J.; Gandhi, N.S.; Mancera, R.L. Molecular dynamics simulation of the phosphorylation-induced conformational changes of a tau peptide fragment. Proteins, 2014, 82(9), 1907-1923. doi: 10.1002/prot.24544 PMID: 24577753</mixed-citation></ref><ref id="B149"><label>149.</label><mixed-citation>Noble, W.; Hanger, D.P.; Miller, C.C.J.; Lovestone, S. The importance of tau phosphorylation for neurodegenerative diseases. Front. Neurol., 2013, 4, 83. doi: 10.3389/fneur.2013.00083 PMID: 23847585</mixed-citation></ref><ref id="B150"><label>150.</label><mixed-citation>Sibille, N.; Huvent, I.; Fauquant, C.; Verdegem, D.; Amniai, L.; Leroy, A.; Wieruszeski, J.M.; Lippens, G.; Landrieu, I. Structural characterization by nuclear magnetic resonance of the impact of phosphorylation in the proline-rich region of the disordered Tau protein. Proteins, 2012, 80(2), 454-462. doi: 10.1002/prot.23210 PMID: 22072628</mixed-citation></ref><ref id="B151"><label>151.</label><mixed-citation>Amniai, L.; Barbier, P.; Sillen, A.; Wieruszeski, J.M.; Peyrot, V.; Lippens, G.; Landrieu, I. Alzheimer disease specific phosphoepitopes of Tau interfere with assembly of tubulin but not binding to microtubules. FASEB J., 2009, 23(4), 1146-1152. doi: 10.1096/fj.08-121590 PMID: 19074508</mixed-citation></ref><ref id="B152"><label>152.</label><mixed-citation>Goode, B.L.; Denis, P.E.; Panda, D.; Radeke, M.J.; Miller, H.P.; Wilson, L.; Feinstein, S.C. Functional interactions between the proline-rich and repeat regions of tau enhance microtubule binding and assembly. Mol. Biol. Cell, 1997, 8(2), 353-365. doi: 10.1091/mbc.8.2.353 PMID: 9190213</mixed-citation></ref><ref id="B153"><label>153.</label><mixed-citation>Gandhi, N.S.; Landrieu, I.; Byrne, C.; Kukic, P.; Amniai, L.; Cantrelle, F.X.; Wieruszeski, J.M.; Mancera, R.L.; Jacquot, Y.; Lippens, G. A phosphorylation-induced turn defines the alzheimers disease AT8 antibody epitope on the tau protein. Angew. Chem. Int. Ed., 2015, 54(23), 6819-6823. doi: 10.1002/anie.201501898 PMID: 25881502</mixed-citation></ref><ref id="B154"><label>154.</label><mixed-citation>Rani, L.; Mallajosyula, S.S. Phosphorylation-induced structural reorganization in tau-paired helical filaments. ACS Chem. Neurosci., 2021, 12(9), 1621-1631. doi: 10.1021/acschemneuro.1c00084 PMID: 33877805</mixed-citation></ref><ref id="B155"><label>155.</label><mixed-citation>Zou, Y.; Guan, L. Unraveling the influence of K280 acetylation on the conformational features of tau core fragment: A molecular dynamics simulation study. Front. Mol. Biosci., 2021, 8, 801577. doi: 10.3389/fmolb.2021.801577 PMID: 34966788</mixed-citation></ref><ref id="B156"><label>156.</label><mixed-citation>Brotzakis, Z.F.; Lindstedt, P.R.; Taylor, R.J.; Rinauro, D.J.; Gallagher, N.C.T.; Bernardes, G.J.L.; Vendruscolo, M. A structural ensemble of a tau-microtubule complex reveals regulatory tau phosphorylation and acetylation mechanisms. ACS Cent. Sci., 2021, 7(12), 1986-1995. doi: 10.1021/acscentsci.1c00585 PMID: 34963892</mixed-citation></ref><ref id="B157"><label>157.</label><mixed-citation>Castro, T.G.; Ferreira, T.; Matamá, T.; Munteanu, F.D.; Cavaco-Paulo, A. Acetylation and phosphorylation processes modulate Taus binding to microtubules: A molecular dynamics study. Biochim. Biophys. Acta, Gen. Subj., 2023, 1867(2), 130276. doi: 10.1016/j.bbagen.2022.130276 PMID: 36372288</mixed-citation></ref><ref id="B158"><label>158.</label><mixed-citation>Leonard, C.; Phillips, C.; McCarty, J. Insight into seeded tau fibril growth from Molecular Dynamics simulation of the Alzheimers disease protofibril core. Front. Mol. Biosci., 2021, 8, 624302. doi: 10.3389/fmolb.2021.624302 PMID: 33816551</mixed-citation></ref><ref id="B159"><label>159.</label><mixed-citation>Munari, F.; Mollica, L.; Valente, C.; Parolini, F.; Kachoie, E.A.; Arrigoni, G.; DOnofrio, M.; Capaldi, S.; Assfalg, M. Structural basis for chaperone-independent ubiquitination of tau protein by its E3 ligase CHIP. Angew. Chem. Int. Ed., 2022, 61(15), e202112374. doi: 10.1002/anie.202112374 PMID: 35107860</mixed-citation></ref><ref id="B160"><label>160.</label><mixed-citation>Mathew, A.T. N-glycosylation induced changes in tau protein dynamics reveal its role in tau misfolding and aggregation: A microsecond long molecular dynamics study. Proteins, 2022, 91(2), 147-162. doi: 10.26434/chemrxiv-2022-5bs5r</mixed-citation></ref><ref id="B161"><label>161.</label><mixed-citation>Cummings, J.; Lee, G.; Ritter, A.; Sabbagh, M.; Zhong, K. Alzheimers disease drug development pipeline: 2019. Alzheimers Dement., 2019, 5(1), 272-293. doi: 10.1016/j.trci.2019.05.008 PMID: 31334330</mixed-citation></ref><ref id="B162"><label>162.</label><mixed-citation>Bush, A.I.; Tanzi, R.E. Therapeutics for Alzheimers disease based on the metal hypothesis. Neurotherapeutics, 2008, 5(3), 421-432. doi: 10.1016/j.nurt.2008.05.001 PMID: 18625454</mixed-citation></ref><ref id="B163"><label>163.</label><mixed-citation>Travis, J. Roche Alzheimers antibody fails to slow cognitive decline in major test; SCIENCEINSIDER, 2022. doi: 10.1126/science.adf8125</mixed-citation></ref><ref id="B164"><label>164.</label><mixed-citation>Fellner, S.; Bauer, B.; Miller, D.S.; Schaffrik, M.; Fankhänel, M.; Spruß, T.; Bernhardt, G.; Graeff, C.; Färber, L.; Gschaidmeier, H.; Buschauer, A.; Fricker, G. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J. Clin. Invest., 2002, 110(9), 1309-1318. doi: 10.1172/JCI0215451 PMID: 12417570</mixed-citation></ref><ref id="B165"><label>165.</label><mixed-citation>Sengupta, A.; Kabat, J.; Novak, M.; Wu, Q.; Grundke-Iqbal, I.; Iqbal, K. Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch. Biochem. Biophys., 1998, 357(2), 299-309. doi: 10.1006/abbi.1998.0813 PMID: 9735171</mixed-citation></ref><ref id="B166"><label>166.</label><mixed-citation>Ishihara, T.; Hong, M.; Zhang, B.; Nakagawa, Y.; Lee, M.K.; Trojanowski, J.Q.; Lee, V.M.Y. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron, 1999, 24(3), 751-762. doi: 10.1016/S0896-6273(00)81127-7 PMID: 10595524</mixed-citation></ref><ref id="B167"><label>167.</label><mixed-citation>Schneider, A.; Biernat, J.; von Bergen, M.; Mandelkow, E.; Mandelkow, E.M. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry, 1999, 38(12), 3549-3558. doi: 10.1021/bi981874p PMID: 10090741</mixed-citation></ref><ref id="B168"><label>168.</label><mixed-citation>Ghoreschi, K.; Laurence, A.; OShea, J.J. Selectivity and therapeutic inhibition of kinases: To be or not to be? Nat. Immunol., 2009, 10(4), 356-360. doi: 10.1038/ni.1701 PMID: 19295632</mixed-citation></ref><ref id="B169"><label>169.</label><mixed-citation>Imahori, K.; Uchida, T. Physiology and pathology of tau protein kinases in relation to Alzheimers disease. J. Biochem., 1997, 121(2), 179-188. PMID: 9089387</mixed-citation></ref><ref id="B170"><label>170.</label><mixed-citation>Hernández, F.; Borrell, J.; Guaza, C.; Avila, J.; Lucas, J.J. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3β in the brain but do not form tau filaments. J. Neurochem., 2002, 83(6), 1529-1533. doi: 10.1046/j.1471-4159.2002.01269.x PMID: 12472906</mixed-citation></ref><ref id="B171"><label>171.</label><mixed-citation>Lee, K.Y.; Clark, A.W.; Rosales, J.L.; Chapman, K.; Fung, T.; Johnston, R.N. Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. Neurosci. Res., 1999, 34(1), 21-29. doi: 10.1016/S0168-0102(99)00026-7 PMID: 10413323</mixed-citation></ref><ref id="B172"><label>172.</label><mixed-citation>Tseng, H.C.; Zhou, Y.; Shen, Y.; Tsai, L.H. A survey of Cdk5 activator p35 and p25 levels in Alzheimers disease brains. FEBS Lett., 2002, 523(1-3), 58-62. doi: 10.1016/S0014-5793(02)02934-4 PMID: 12123804</mixed-citation></ref><ref id="B173"><label>173.</label><mixed-citation>Noble, W.; Olm, V.; Takata, K.; Casey, E.; Mary, O.; Meyerson, J.; Gaynor, K.; LaFrancois, J.; Wang, L.; Kondo, T.; Davies, P.; Burns, M.; Veeranna; Nixon, R.; Dickson, D.; Matsuoka, Y.; Ahlijanian, M.; Lau, L.F.; Duff, K. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron, 2003, 38(4), 555-565. doi: 10.1016/S0896-6273(03)00259-9 PMID: 12765608</mixed-citation></ref><ref id="B174"><label>174.</label><mixed-citation>Wen, Y.; Planel, E.; Herman, M.; Figueroa, H.Y.; Wang, L.; Liu, L.; Lau, L.F.; Yu, W.H.; Duff, K.E. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 β mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J. Neurosci., 2008, 28(10), 2624-2632. doi: 10.1523/JNEUROSCI.5245-07.2008 PMID: 18322105</mixed-citation></ref><ref id="B175"><label>175.</label><mixed-citation>Drewes, G.; Ebneth, A.; Preuss, U.; Mandelkow, E.M.; Mandelkow, E. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell, 1997, 89(2), 297-308. doi: 10.1016/S0092-8674(00)80208-1 PMID: 9108484</mixed-citation></ref><ref id="B176"><label>176.</label><mixed-citation>Noble, W.; Planel, E.; Zehr, C.; Olm, V.; Meyerson, J.; Suleman, F.; Gaynor, K.; Wang, L.; LaFrancois, J.; Feinstein, B.; Burns, M.; Krishnamurthy, P.; Wen, Y.; Bhat, R.; Lewis, J.; Dickson, D.; Duff, K. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. USA, 2005, 102(19), 6990-6995. doi: 10.1073/pnas.0500466102 PMID: 15867159</mixed-citation></ref><ref id="B177"><label>177.</label><mixed-citation>Hampel, H.; Ewers, M.; Bürger, K.; Annas, P.; Mörtberg, A.; Bogstedt, A.; Frölich, L.; Schröder, J.; Schönknecht, P.; Riepe, M.W.; Kraft, I.; Gasser, T.; Leyhe, T.; Möller, H.J.; Kurz, A.; Basun, H. Lithium trial in Alzheimers disease: A randomized, single-blind, placebo-controlled, multicenter 10-week study. J. Clin. Psychiatry, 2009, 70(6), 922-931. doi: 10.4088/JCP.08m04606 PMID: 19573486</mixed-citation></ref><ref id="B178"><label>178.</label><mixed-citation>Gitlin, M. Lithium side effects and toxicity: Prevalence and management strategies. Int. J. Bipolar Disord., 2016, 4(1), 27. doi: 10.1186/s40345-016-0068-y PMID: 27900734</mixed-citation></ref><ref id="B179"><label>179.</label><mixed-citation>Bhat, R.; Xue, Y.; Berg, S.; Hellberg, S.; Ormö, M.; Nilsson, Y.; Radesäter, A.C.; Jerning, E.; Markgren, P.O.; Borgegård, T.; Nylöf, M.; Giménez-Cassina, A.; Hernández, F.; Lucas, J.J.; Díaz-Nido, J.; Avila, J. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem., 2003, 278(46), 45937-45945. doi: 10.1074/jbc.M306268200 PMID: 12928438</mixed-citation></ref><ref id="B180"><label>180.</label><mixed-citation>Nakashima, H.; Ishihara, T.; Suguimoto, P.; Yokota, O.; Oshima, E.; Kugo, A.; Terada, S.; Hamamura, T.; Trojanowski, J.Q.; Lee, V.M.Y.; Kuroda, S. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol., 2005, 110(6), 547-556. doi: 10.1007/s00401-005-1087-4 PMID: 16228182</mixed-citation></ref><ref id="B181"><label>181.</label><mixed-citation>Engel, T.; Goñi-Oliver, P.; Lucas, J.J.; Avila, J.; Hernández, F. Chronic lithium administration to FTDP-17 tau and GSK-3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J. Neurochem., 2006, 99(6), 1445-1455. doi: 10.1111/j.1471-4159.2006.04139.x PMID: 17059563</mixed-citation></ref><ref id="B182"><label>182.</label><mixed-citation>Selenica, M-L.; Jensen, H.S.; Larsen, A.K.; Pedersen, M.L.; Helboe, L.; Leist, M.; Lotharius, J. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br. J. Pharmacol., 2007, 152(6), 959-979. doi: 10.1038/sj.bjp.0707471 PMID: 17906685</mixed-citation></ref><ref id="B183"><label>183.</label><mixed-citation>Naujok, O.; Lentes, J.; Diekmann, U.; Davenport, C.; Lenzen, S. Cytotoxicity and activation of the Wnt/beta-catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors. BMC Res. Notes, 2014, 7(1), 273. doi: 10.1186/1756-0500-7-273 PMID: 24779365</mixed-citation></ref><ref id="B184"><label>184.</label><mixed-citation>Navarro-Retamal, C.; Caballero, J. Molecular modeling of tau proline-directed protein kinase (PDPK) inhibitors. In: Computational Modeling of Drugs Against Alzheimers Disease; Roy, K., Ed.; Springer New York: New York, NY, 2018; pp. 305-345. doi: 10.1007/978-1-4939-7404-7_13</mixed-citation></ref><ref id="B185"><label>185.</label><mixed-citation>Congdon, E.E.; Sigurdsson, E.M. Tau-targeting therapies for Alzheimer disease. Nat. Rev. Neurol., 2018, 14(7), 399-415. doi: 10.1038/s41582-018-0013-z PMID: 29895964</mixed-citation></ref><ref id="B186"><label>186.</label><mixed-citation>Courade, J.P.; Angers, R.; Mairet-Coello, G.; Pacico, N.; Tyson, K.; Lightwood, D.; Munro, R.; McMillan, D.; Griffin, R.; Baker, T.; Starkie, D.; Nan, R.; Westwood, M.; Mushikiwabo, M.L.; Jung, S.; Odede, G.; Sweeney, B.; Popplewell, A.; Burgess, G.; Downey, P.; Citron, M. Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau. Acta Neuropathol., 2018, 136(5), 729-745. doi: 10.1007/s00401-018-1911-2 PMID: 30238240</mixed-citation></ref><ref id="B187"><label>187.</label><mixed-citation>Jadhav, S.; Avila, J.; Schöll, M.; Kovacs, G.G.; Kövari, E.; Skrabana, R.; Evans, L.D.; Kontsekova, E.; Malawska, B.; de Silva, R.; Buee, L.; Zilka, N. A walk through tau therapeutic strategies. Acta Neuropathol. Commun., 2019, 7(1), 22. doi: 10.1186/s40478-019-0664-z PMID: 30767766</mixed-citation></ref><ref id="B188"><label>188.</label><mixed-citation>Pradeepkiran, J.; Reddy, P. Structure based design and molecular docking studies for phosphorylated tau inhibitors in alzheimers disease. Cells, 2019, 8(3), 260. doi: 10.3390/cells8030260 PMID: 30893872</mixed-citation></ref><ref id="B189"><label>189.</label><mixed-citation>Halliday, M.; Radford, H.; Zents, K.A.M.; Molloy, C.; Moreno, J.A.; Verity, N.C.; Smith, E.; Ortori, C.A.; Barrett, D.A.; Bushell, M.; Mallucci, G.R. Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice. Brain, 2017, 140(6), 1768-1783. doi: 10.1093/brain/awx074 PMID: 28430857</mixed-citation></ref><ref id="B190"><label>190.</label><mixed-citation>SantaCruz, K.; Lewis, J.; Spires, T.; Paulson, J.; Kotilinek, L.; Ingelsson, M.; Guimaraes, A.; DeTure, M.; Ramsden, M.; McGowan, E.; Forster, C.; Yue, M.; Orne, J.; Janus, C.; Mariash, A.; Kuskowski, M.; Hyman, B.; Hutton, M.; Ashe, K.H. Tau suppression in a neurodegenerative mouse model improves memory function. Science, 2005, 309(5733), 476-481. doi: 10.1126/science.1113694 PMID: 16020737</mixed-citation></ref><ref id="B191"><label>191.</label><mixed-citation>Guo, N.; Peng, Z. MG132, a proteasome inhibitor, induces apoptosis in tumor cells. Asia Pac. J. Clin. Oncol., 2013, 9(1), 6-11. doi: 10.1111/j.1743-7563.2012.01535.x PMID: 22897979</mixed-citation></ref><ref id="B192"><label>192.</label><mixed-citation>Choi, H.; Kim, H.J.; Yang, J.; Chae, S.; Lee, W.; Chung, S.; Kim, J.; Choi, H.; Song, H.; Lee, C.K.; Jun, J.H.; Lee, Y.J.; Lee, K.; Kim, S.; Sim, H.; Choi, Y.I.; Ryu, K.H.; Park, J.C.; Lee, D.; Han, S.H.; Hwang, D.; Kyung, J.; Mook-Jung, I. Acetylation changes tau interactome to degrade tau in Alzheimers disease animal and organoid models. Aging Cell, 2020, 19(1), e13081. doi: 10.1111/acel.13081 PMID: 31763743</mixed-citation></ref><ref id="B193"><label>193.</label><mixed-citation>Tarjányi, O.; Haerer, J.; Vecsernyés, M.; Berta, G.; Stayer-Harci, A.; Balogh, B.; Farkas, K.; Boldizsár, F.; Szeberényi, J.; Sétáló, G., Jr Prolonged treatment with the proteasome inhibitor MG-132 induces apoptosis in PC12 rat pheochromocytoma cells. Sci. Rep., 2022, 12(1), 5808. doi: 10.1038/s41598-022-09763-z PMID: 35388084</mixed-citation></ref><ref id="B194"><label>194.</label><mixed-citation>Ohkusu-Tsukada, K.; Ito, D.; Takahashi, K. The role of proteasome inhibitor MG132 in 2,4-dinitrofluorobenzene-induced atopic dermatitis in NC/Nga mice. Int. Arch. Allergy Immunol., 2018, 176(2), 91-100. doi: 10.1159/000488155 PMID: 29669333</mixed-citation></ref><ref id="B195"><label>195.</label><mixed-citation>Corpas, R.; Griñán-Ferré, C.; Palomera-Ávalos, V.; Porquet, D.; de Frutos, P.G.; Cozzolino, S.M.F.; Rodríguez-Farré, E.; Pallàs, M.; Sanfeliu, C.; Cardoso, B.R. Melatonin induces mechanisms of brain resilience against neurodegeneration. J. Pineal Res., 2018, 65(4), e12515. doi: 10.1111/jpi.12515 PMID: 29907977</mixed-citation></ref><ref id="B196"><label>196.</label><mixed-citation>Seidler, P.M.; Boyer, D.R.; Rodriguez, J.A.; Sawaya, M.R.; Cascio, D.; Murray, K.; Gonen, T.; Eisenberg, D.S. Structure-based inhibitors of tau aggregation. Nat. Chem., 2018, 10(2), 170-176. doi: 10.1038/nchem.2889 PMID: 29359764</mixed-citation></ref><ref id="B197"><label>197.</label><mixed-citation>Nixon, R.A. Autophagy in neurodegenerative disease: Friend, foe or turncoat? Trends Neurosci., 2006, 29(9), 528-535. doi: 10.1016/j.tins.2006.07.003 PMID: 16859759</mixed-citation></ref><ref id="B198"><label>198.</label><mixed-citation>Penke, B.; Bogár, F.; Crul, T.; Sántha, M.; Tóth, M.; Vígh, L. Heat shock proteins and autophagy pathways in neuroprotection: From molecular bases to pharmacological interventions. Int. J. Mol. Sci., 2018, 19(1), 325. doi: 10.3390/ijms19010325 PMID: 29361800</mixed-citation></ref><ref id="B199"><label>199.</label><mixed-citation>Dickey, C.A.; Dunmore, J.; Lu, B.; Wang, J.W.; Lee, W.C.; Kamal, A.; Burrows, F.; Eckman, C.; Hutton, M.; Petrucelli, L. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J., 2006, 20(6), 753-755. doi: 10.1096/fj.05-5343fje PMID: 16464956</mixed-citation></ref><ref id="B200"><label>200.</label><mixed-citation>Zhang, H.; Burrows, F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. Med., 2004, 82(8), 488-499. doi: 10.1007/s00109-004-0549-9 PMID: 15168026</mixed-citation></ref><ref id="B201"><label>201.</label><mixed-citation>Jilani, K.; Qadri, S.M.; Lang, F. Geldanamycin-induced phosphatidylserine translocation in the erythrocyte membrane. Cell. Physiol. Biochem., 2013, 32(6), 1600-1609. doi: 10.1159/000356596 PMID: 24335345</mixed-citation></ref><ref id="B202"><label>202.</label><mixed-citation>Ochel, H.J.; Eichhorn, K.; Gademann, G. Geldanamycin: The prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones. Cell Stress Chaperones, 2001, 6(2), 105-112. doi: 10.1379/1466-1268(2001)0062.0.CO;2 PMID: 11599571</mixed-citation></ref><ref id="B203"><label>203.</label><mixed-citation>Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M.F.; Fritz, L.C.; Burrows, F.J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature, 2003, 425(6956), 407-410. doi: 10.1038/nature01913 PMID: 14508491</mixed-citation></ref><ref id="B204"><label>204.</label><mixed-citation>Vilenchik, M.; Solit, D.; Basso, A.; Huezo, H.; Lucas, B.; He, H.; Rosen, N.; Spampinato, C.; Modrich, P.; Chiosis, G. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem. Biol., 2004, 11(6), 787-797. doi: 10.1016/j.chembiol.2004.04.008 PMID: 15217612</mixed-citation></ref><ref id="B205"><label>205.</label><mixed-citation>Hamano, T.; Gendron, T.F.; Causevic, E.; Yen, S.H.; Lin, W.L.; Isidoro, C.; DeTure, M.; Ko, L. Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild- type tau expression. Eur. J. Neurosci., 2008, 27(5), 1119-1130. doi: 10.1111/j.1460-9568.2008.06084.x PMID: 18294209</mixed-citation></ref><ref id="B206"><label>206.</label><mixed-citation>Berger, Z.; Ravikumar, B.; Menzies, F.M.; Oroz, L.G.; Underwood, B.R.; Pangalos, M.N.; Schmitt, I.; Wullner, U.; Evert, B.O.; OKane, C.J.; Rubinsztein, D.C. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet., 2006, 15(3), 433-442. doi: 10.1093/hmg/ddi458 PMID: 16368705</mixed-citation></ref><ref id="B207"><label>207.</label><mixed-citation>Morita, T.; Sobue, K. Specification of neuronal polarity regulated by local translation of CRMP2 and Tau via the mTOR-p70S6K pathway. J. Biol. Chem., 2009, 284(40), 27734-27745. doi: 10.1074/jbc.M109.008177 PMID: 19648118</mixed-citation></ref><ref id="B208"><label>208.</label><mixed-citation>Bresinsky, M.; Strasser, J.M.; Vallaster, B.; Liu, P.; McCue, W.M.; Fuller, J.; Hubmann, A.; Singh, G.; Nelson, K.M.; Cuellar, M.E.; Wilmot, C.M.; Finzel, B.C.; Ashe, K.H.; Walters, M.A.; Pockes, S. Structure-based design and biological evaluation of novel caspase-2 inhibitors based on the peptide AcVDVAD-CHO and the caspase-2-mediated tau cleavage sequence YKPVD314. ACS Pharmacol. Transl. Sci., 2022, 5(1), 20-40. doi: 10.1021/acsptsci.1c00251 PMID: 35059567</mixed-citation></ref><ref id="B209"><label>209.</label><mixed-citation>Yuzwa, S.A.; Macauley, M.S.; Heinonen, J.E.; Shan, X.; Dennis, R.J.; He, Y.; Whitworth, G.E.; Stubbs, K.A.; McEachern, E.J.; Davies, G.J.; Vocadlo, D.J. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat. Chem. Biol., 2008, 4(8), 483-490. doi: 10.1038/nchembio.96 PMID: 18587388</mixed-citation></ref><ref id="B210"><label>210.</label><mixed-citation>Yu, Y.; Zhang, L.; Li, X.; Run, X.; Liang, Z.; Li, Y.; Liu, Y.; Lee, M.H.; Grundke-Iqbal, I.; Iqbal, K.; Vocadlo, D.J.; Liu, F.; Gong, C.X. Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation. PLoS One, 2012, 7(4), e35277. doi: 10.1371/journal.pone.0035277 PMID: 22536363</mixed-citation></ref><ref id="B211"><label>211.</label><mixed-citation>Selnick, H.G.; Hess, J.F.; Tang, C.; Liu, K.; Schachter, J.B.; Ballard, J.E.; Marcus, J.; Klein, D.J.; Wang, X.; Pearson, M.; Savage, M.J.; Kaul, R.; Li, T.S.; Vocadlo, D.J.; Zhou, Y.; Zhu, Y.; Mu, C.; Wang, Y.; Wei, Z.; Bai, C.; Duffy, J.L.; McEachern, E.J. Discovery of MK-8719, a potent o-glcnacase inhibitor as a potential treatment for tauopathies. J. Med. Chem., 2019, 62(22), 10062-10097. doi: 10.1021/acs.jmedchem.9b01090 PMID: 31487175</mixed-citation></ref><ref id="B212"><label>212.</label><mixed-citation>ASN90 2022. Available from: https://www.alzforum.org/therapeutics/asn90</mixed-citation></ref><ref id="B213"><label>213.</label><mixed-citation>Yuzwa, S.A.; Shan, X.; Macauley, M.S.; Clark, T.; Skorobogatko, Y.; Vosseller, K.; Vocadlo, D.J. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat. Chem. Biol., 2012, 8(4), 393-399. doi: 10.1038/nchembio.797 PMID: 22366723</mixed-citation></ref><ref id="B214"><label>214.</label><mixed-citation>Younes, M.; Aggett, P.; Aguilar, F.; Crebelli, R.; Dusemund, B.; Filipič, M.; Frutos, M.J.; Galtier, P.; Gott, D.; Gundert-Remy, U.; Lambré, C.; Leblanc, J.C.; Lillegaard, I.T.; Moldeus, P.; Mortensen, A.; Oskarsson, A.; Stankovic, I.; Waalkens-Berendsen, I.; Woutersen, R.A.; Andrade, R.J.; Fortes, C.; Mosesso, P.; Restani, P.; Arcella, D.; Pizzo, F.; Smeraldi, C.; Wright, M. Scientific opinion on the safety of green tea catechins. EFSA J., 2018, 16(4), e05239. PMID: 32625874</mixed-citation></ref><ref id="B215"><label>215.</label><mixed-citation>Mereles, D.; Hunstein, W. Epigallocatechin-3-gallate (EGCG) for clinical trials: More pitfalls than promises? Int. J. Mol. Sci., 2011, 12(9), 5592-5603. doi: 10.3390/ijms12095592 PMID: 22016611</mixed-citation></ref><ref id="B216"><label>216.</label><mixed-citation>Sonawane, S.K.; Chinnathambi, S. Epigallocatechin-3-gallate modulates tau post-translational modifications and cytoskeletal network. Oncotarget, 2021, 12(11), 1083-1099. doi: 10.18632/oncotarget.27963 PMID: 34084282</mixed-citation></ref><ref id="B217"><label>217.</label><mixed-citation>Seidler, P.M.; Murray, K.A.; Boyer, D.R.; Ge, P.; Sawaya, M.R.; Hu, C.J.; Cheng, X.; Abskharon, R.; Pan, H.; DeTure, M.A.; Williams, C.K.; Dickson, D.W.; Vinters, H.V.; Eisenberg, D.S. Structure-based discovery of small molecules that disaggregate Alzheimers disease tissue derived tau fibrils in vitro. Nat. Commun., 2022, 13(1), 5451. doi: 10.1038/s41467-022-32951-4 PMID: 36114178</mixed-citation></ref><ref id="B218"><label>218.</label><mixed-citation>Inuzuka, H.; Liu, J.; Wei, W.; Rezaeian, A.H. PROTAC technology for the treatment of Alzheimers disease: Advances and perspectives. Acta Materia Medica, 2022, 1(1), 24-41. doi: 10.15212/AMM-2021-0001 PMID: 35237768</mixed-citation></ref><ref id="B219"><label>219.</label><mixed-citation>Li, C.; Götz, J. Tau-based therapies in neurodegeneration: Opportunities and challenges. Nat. Rev. Drug Discov., 2017, 16(12), 863-883. doi: 10.1038/nrd.2017.155 PMID: 28983098</mixed-citation></ref></ref-list></back></article>
